Yuli Xie obtained his B.S. in chemistry from Nankai University and his Ph.D. in medicinal chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He did his postdoctoral research in Columbia University. Afterwards, he has taken multiple leadership positions in reputable pharmaceutical companies and research institutes including Columbia medical school, Yangtze River Pharmaceuticals, Otsuka and WuXi AppTec, within creasing responsibilities in various disciplines spanning early drug discovery, project and portfolio management.
Lihui Qian graduated from the Department of Biochemistry of Nanjing University with B.S. in biochemistry. She holds a Ph.D. in molecular and cellular biology from Cornell University/Sloan-Kettering Cancer Institute, and did her postdoc work in Novartis Institute of Biomedical Research. She has been engaged in research and project management at Novartis and the Chinese Academy of Sciences, with experiences in in vivo and in vitro drug screening, target verification and project management.
Yingming Wu obtained B.S. in chemistry from East China University of Science and Technology and his Ph.D. in chemistry from Yunnan University. He did his post-doctorate study in Hong Kong University of Science and Technology. He has served as as project leaders in various pharmaceutical companies including Novartis, Otsuka, and has rich experience in medicinal chemistry, process chemistry, target-based drug design and project management, and is familiar with drug discovery in areas of oncology, metabolism and central nervous diseases.